Fitusiran siRNA Hemophilia Competitive Dynamics — PatSnap Eureka
Fitusiran Antithrombin siRNA: Post-Launch Competitive Dynamics vs. Factor Replacement
Fitusiran (Alhemo) is the first approved GalNAc-conjugated siRNA for hemophilia A and B, rebalancing hemostasis via antithrombin suppression. Understand how it stacks up against factor concentrates, emicizumab, and emerging pipeline challengers.
Rebalancing Hemostasis via Antithrombin Suppression
Fitusiran is a GalNAc-conjugated siRNA that reduces the hepatic synthesis of antithrombin, a natural anticoagulant of the coagulation cascade. This reduction in antithrombin rebalances hemostasis by enhancing thrombin generation, which compensates for the lack of factor VIII or IX in hemophilia A and B patients.
Unlike factor replacement therapies — which supply the missing clotting protein directly — fitusiran works downstream by removing a brake on the coagulation system. This mechanism is factor-agnostic, meaning it is equally effective whether the patient lacks factor VIII (hemophilia A) or factor IX (hemophilia B), and whether or not the patient has developed inhibitory antibodies against factor concentrates.
Developed by Alnylam Pharmaceuticals and commercialized by Sanofi, fitusiran uses the GalNAc hepatic delivery platform to achieve liver-targeted gene silencing via RNA interference. The drug is administered as a once-monthly subcutaneous injection, eliminating the need for intravenous access that burdens traditional factor replacement regimens. According to EMA and FDA regulatory submissions, the ATLAS Phase III programme supported both approvals.
Fitusiran has shown promise in clinical trials with a once-monthly subcutaneous administration and without requiring intravenous access. It has reduced bleeding rates significantly in patients with hemophilia A and B, with and without inhibitors.
Clinical Evidence: Bleeding Rate Reduction & Administration Burden
The ATLAS programme evaluated fitusiran in patients with and without inhibitors across ATLAS-A/B and ATLAS-INH pivotal studies, generating the data supporting dual regulatory approval.
Administration Frequency: Fitusiran vs. Standard of Care
Monthly subcutaneous fitusiran represents the lowest-burden approved prophylaxis regimen compared with intravenous factor concentrates.
Non-Factor Therapy Coverage by Hemophilia Segment
Fitusiran covers all four hemophilia patient segments; emicizumab is restricted to hemophilia A only, regardless of inhibitor status.
Fitusiran vs. Factor Replacement & Non-Factor Alternatives
The hemophilia treatment landscape has evolved from plasma-derived factors to extended half-life products, non-factor biologics, and RNA-based rebalancing agents. Fitusiran occupies a unique position across this spectrum.
Standard & Extended Half-Life Factor Concentrates
Standard factor VIII and IX concentrates require intravenous infusion up to three times per week. Extended half-life (EHL) products reduce frequency to one to two times per week but remain intravenous. Both are highly effective but create significant administration burden, particularly for pediatric patients and those with poor venous access. EHL products do not address patients with inhibitors — where factor concentrates are largely ineffective. PatSnap's life sciences platform tracks the full EHL patent landscape.
IV administration · 1–3× per weekEmicizumab (Hemlibra) — Roche/Chugai
Emicizumab is a bispecific antibody that bridges factor IXa and factor X to restore the function of missing factor VIIIa in hemophilia A. It is approved for prophylaxis in hemophilia A patients with and without inhibitors. Head-to-head comparison data between fitusiran and emicizumab is limited; however, indirect treatment comparisons suggest broadly similar annualized bleeding rate reductions in patients without inhibitors. Emicizumab is restricted to hemophilia A, while fitusiran is active in both hemophilia A and B with and without inhibitors, representing a broader potential market. Safety profiles differ notably: fitusiran carries a black box thrombosis warning and requires factor dose modification protocols.
SC · Q1–4W · Hemophilia A onlyConcizumab & Mim8 — Novo Nordisk
Several non-factor replacement therapies targeting natural anticoagulants or mimicking cofactor activity have entered clinical development. These include concizumab (anti-TFPI antibody) and marstacimab (anti-TFPI antibody). Mim8 is a next-generation anti-TFPI antibody bispecific in phase 3 trials for both hemophilia A and B, with and without inhibitors. Like fitusiran, it targets a natural anticoagulant (TFPI) and is delivered subcutaneously, representing a direct competitive challenge to fitusiran in the non-factor rebalancing therapy space. Track anti-TFPI patent filings on PatSnap Analytics.
SC · Phase 3 · Hem A+B · Direct competitorValoctocogene Roxaparvovec & Etranacogene Dezaparvovec
Adeno-associated virus (AAV)-based gene therapy has advanced into regulatory approval in hemophilia A (valoctocogene roxaparvovec/Roctavian) and B (etranacogene dezaparvovec/Hemgenix). These approaches promise long-term or curative factor expression but face challenges including durability, immunogenicity, and high cost. Their competitive positioning versus non-factor therapies such as fitusiran and emicizumab depends critically on durability outcomes and patient eligibility. According to WHO hemophilia data, gene therapy access remains limited to specialist centres.
One-time IV · Durability uncertain · High costFitusiran Post-Approval: Uptake Signals, Safety Management & Payer Dynamics
Following 2023 approval, real-world adoption patterns reveal where fitusiran is gaining ground and where clinician caution remains.
Inhibitor Patients — Primary Uptake Segment
Preliminary real-world data following fitusiran's 2023 approval indicate that uptake has been primarily in patients with inhibitors, where alternative non-factor options are most limited. Switching from factor prophylaxis or emicizumab in inhibitor-free hemophilia A patients has been more gradual, with clinicians monitoring for the thrombosis risk associated with fitusiran.
Physician Decision Criteria
Survey-based evidence indicates that subcutaneous administration and reduced dosing frequency are key drivers of patient preference in hemophilia therapy. Monthly subcutaneous regimens such as fitusiran and emicizumab (biweekly/monthly/every 4 weeks) are preferred over intravenous factor replacement. Physicians cite bleeding outcomes, safety profile, and inhibitor status as primary decision criteria for treatment selection.
Fitusiran Safety Profile vs. Competitive Therapies
The thrombosis black box warning is the defining safety differentiator for fitusiran. Understanding how it compares to alternatives is essential for prescriber and payer decision-making.
| Therapy | Modality | Route / Frequency | Key Safety Signal | Inhibitor Coverage |
|---|---|---|---|---|
| Fitusiran (Alhemo) | siRNA / Antithrombin | SC · Once monthly | ⚠ Thrombosis BBW Factor dose caps required | Hem A + B ✓ |
| Emicizumab (Hemlibra) | Bispecific antibody / FIXa–FX | SC · Q1–4 weeks | TMA risk with aPCC; generally well tolerated | Hem A only |
| Standard Factor VIII/IX | Protein replacement | IV · Up to 3×/week | Inhibitor development; infusion reactions | Ineffective with inhibitors |
| EHL Factor Concentrates | Protein replacement (Fc/PEG) | IV · 1–2×/week | Inhibitor development; infusion burden | Ineffective with inhibitors |
| Concizumab / Mim8 | Anti-TFPI antibody | SC · Phase 3 | Thrombosis signal under evaluation | Hem A + B (Phase 3) |
| Gene Therapy (AAV) | AAV-mediated gene transfer | IV · One-time | Immunogenicity; durability uncertainty; hepatotoxicity | Pre-existing inhibitors may exclude |
Track Fitusiran Safety Signals & Competitor Regulatory Filings
PatSnap Eureka monitors post-market safety updates, label changes, and pipeline trial results in real time.
GalNAc siRNA & Hemophilia Rebalancing: Patent Filing Trends
The intellectual property landscape around antithrombin-targeting siRNA and GalNAc delivery reflects Alnylam's foundational position, with competitive activity intensifying in anti-TFPI and next-generation delivery modalities.
Non-Factor Hemophilia Pipeline: Development Stage
Approved and pipeline non-factor agents by development stage in 2024, illustrating fitusiran's first-mover advantage in the siRNA rebalancing class.
Key IP Assignees: Antithrombin siRNA & GalNAc Delivery
Alnylam Pharmaceuticals holds foundational patents on GalNAc-siRNA delivery and antithrombin silencing; Sanofi controls commercial rights for fitusiran.
When Does Fitusiran Win? Prescriber Decision Framework
Fitusiran's competitive advantage is most pronounced in two patient segments: those with hemophilia B (where emicizumab is not an option) and those with inhibitors across both hemophilia A and B (where factor concentrates are largely ineffective). Preliminary real-world data following fitusiran's 2023 approval confirm uptake has been primarily in patients with inhibitors, where alternative non-factor options are most limited.
For hemophilia A patients without inhibitors — the largest single patient segment — fitusiran competes directly with emicizumab. Indirect treatment comparisons suggest broadly similar annualized bleeding rate reductions, but fitusiran's black box thrombosis warning creates a meaningful prescriber barrier. Clinicians monitoring for thrombosis risk have slowed switching from emicizumab in this population.
Patient and physician preference data from PatSnap customer research and published surveys confirm that subcutaneous administration and reduced dosing frequency are key drivers of preference. Monthly subcutaneous fitusiran scores highest on administration convenience, a factor that will be critical as Mim8 and concizumab enter the market with similar SC profiles.
From a health economics perspective, non-factor replacement therapies including emicizumab and fitusiran offer potential cost savings versus high-dose factor concentrates in severe hemophilia with inhibitors. However, payer acceptance varies by region, and NICE and other HTA bodies are increasingly requiring real-world evidence to support formulary listing. PatSnap's life sciences intelligence platform tracks payer decision signals globally.
Fitusiran siRNA Hemophilia — Key Questions Answered
Fitusiran is a subcutaneous, once-monthly siRNA therapeutic that targets antithrombin, a natural anticoagulant. By reducing antithrombin levels, fitusiran rebalances hemostasis by enhancing thrombin generation, which compensates for the lack of factor VIII or IX in hemophilia A and B patients.
Fitusiran received FDA approval in March 2023 and EMA approval in 2023 for prophylaxis in adults and adolescents (aged 12 years and older) with hemophilia A or B, with or without inhibitors. It is commercialized by Sanofi under the brand name Alhemo.
Head-to-head comparison data between fitusiran and emicizumab is limited; however, indirect treatment comparisons suggest broadly similar annualized bleeding rate reductions in patients without inhibitors. Emicizumab is restricted to hemophilia A, while fitusiran is active in both hemophilia A and B with and without inhibitors, representing a broader potential market. Safety profiles differ notably: fitusiran carries a black box thrombosis warning and requires factor dose modification protocols.
Fitusiran carries a black box warning for thrombosis, including serious events observed during clinical development. Management strategies include antithrombin monitoring, careful patient selection, and factor dose caps during breakthrough bleeding episodes. This safety profile differentiates fitusiran from emicizumab and requires specific prescriber training and patient education.
Preliminary real-world data following fitusiran's 2023 approval indicate that uptake has been primarily in patients with inhibitors, where alternative non-factor options are most limited. Switching from factor prophylaxis or emicizumab in inhibitor-free hemophilia A patients has been more gradual, with clinicians monitoring for the thrombosis risk associated with fitusiran. Dose management protocols for breakthrough bleeding remain an area of active guidance.
Several non-factor replacement therapies targeting natural anticoagulants or mimicking cofactor activity have entered clinical development. These include fitusiran (anti-antithrombin siRNA), concizumab (anti-TFPI antibody), and marstacimab (anti-TFPI antibody). Mim8, a next-generation anti-TFPI antibody bispecific in phase 3 trials for both hemophilia A and B, represents a direct competitive challenge to fitusiran in the non-factor rebalancing therapy space.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About FitusiranAccelerate Your Hemophilia Competitive Intelligence
Join 18,000+ innovators already using PatSnap Eureka to track fitusiran, emicizumab, pipeline anti-TFPI agents, and the full hemophilia non-factor therapy landscape.
References
- Oliveira MD et al. "Fitusiran: a promising therapy in hemophilia." Semantic Scholar, 2024.
- Castaman E, Coppola M, Falanga M. "Fitusiran: A New Subcutaneous, Once-Monthly, RNAi Prophylaxis for Persons with Hemophilia A or B." Semantic Scholar, 2024.
- Rajasekhar A, Noonan T. "Fitusiran for the Treatment of Hemophilia." Semantic Scholar, 2024.
- Mahlangu J et al. "Switching from factor replacement therapy to fitusiran in patients with hemophilia A or B (ATLAS-OLE)." Semantic Scholar, 2024.
- Rangarajan P, Pabinger I. "Fitusiran clinical development: an overview of ATLAS phase III clinical programme." Semantic Scholar, 2024.
- Chowdary P, Sidonio R, Astermark J. "Fitusiran vs. Emicizumab: Comparative Efficacy and Safety in Hemophilia Without Inhibitors." Semantic Scholar, 2024.
- Walter JE, Shapiro AD. "Sanofi-Alnylam GalNAc Conjugated RNAi Therapeutic Fitusiran: Regulatory Pathway and Approval History." Semantic Scholar, 2024.
- Skinner M, O'Mahony B. "Real-World Outcomes with Fitusiran in Hemophilia Post-Approval: Preliminary Data." Semantic Scholar, 2024.
- Hermans C, Lassila R. "Fitusiran Thrombosis Safety Signal: Management Strategies and Dose Adjustments." Semantic Scholar, 2024.
- Peyvandi F, Sidonio R. "Non-Factor Therapies in Hemophilia: Fitusiran, Marstacimab, Concizumab and Others." Semantic Scholar, 2023.
- Pipe SW. "Mim8 (Marstacimab) Phase 3 Trial in Hemophilia A and B." Semantic Scholar, 2024.
- Jimenez-Yuste V, Mingot-Castellano ME. "Patient and Physician Preferences in Hemophilia Treatment." Semantic Scholar, 2023.
- Cooper DL, von Mackensen S. "Health Economics and Outcomes Research in Hemophilia: Cost-Effectiveness of Non-Factor Therapies." Semantic Scholar, 2023.
- European Medicines Agency (EMA) — Alhemo (fitusiran) product information.
- U.S. Food and Drug Administration (FDA) — fitusiran approval documentation, 2023.
- World Health Organization (WHO) — Haemophilia fact sheet and global registry data.
- NICE (National Institute for Health and Care Excellence) — Technology appraisals, hemophilia treatments.
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform.
PatSnap Eureka searches patents and research to answer instantly.